Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy

Journal of Translational Medicine

Research

A. Agrawal¹  H. Bansal¹  J. Parcero²  T. Ichim²  J. Lopez²  J. Perez²  K. Comella³ 

[1] Consultant Regenerative Medicine, Mother Cell Spinal Injury and Stem Cell Research, Anupam Hospital, 263153, Rudrapur, Uttarakhand, India;Regenerative Medicine Institute, Tijuana, Mexico;US Stem Cell, Inc, Sunrise, FL, USA;

关键词: Stromal vascular fraction (SVF);    Adipose derived stromal/stem cells (ADSCs);    Stem cells;    Adipose tissue;    Connective tissue;    Ischemic cardiomyopathy;    Cell therapy;   

DOI  :  10.1186/s12967-016-0918-5

 received in 2016-04-22, accepted in 2016-05-20,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundStromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of fat tissue. The SVF contains a mixture of cells including ADSCs and growth factors and has been depleted of the adipocyte (fat cell) population. We evaluated the safety and efficacy of administering SVF intra-myocardially into patients with chronic ischemic cardiomyopathy.MethodsA total of 28 patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue. The fat was separated to isolate the SVF and the cells were delivered into the akinetic myocardial scar region using a transendocardial delivery system (MyoCath®) in patients who had experienced a previous myocardial infarct. The subjects were then monitored for adverse events, ejection fraction via echocardiogram and six-minute walk test (6MWT) over a period of 6 months.ResultsThe average EF was 29 % at baseline and significantly increased to 35 % at both 3 and 6 months. Patients walked an average of 349 m at baseline and demonstrated a statistically significant improvement at 3 and 6 months’ post treatment of more than 80 m.ConclusionsOverall, patients were pleased with the treatment results. More importantly, the procedure demonstrated a strong safety profile with no severe adverse events or complications linked to the therapy.Trial registration NCT01502514Name of registry: http://www.clinicaltrials.govURL: https://www.clinicaltrials.gov/ct2/show/NCT01502514?term=adipose+cells+heart&rank=4Date of registration: December 27, 2011Date of enrollment: January 2012

【 授权许可】

CC BY   
© The Author(s) 2016